{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:05:29Z","timestamp":1773299129939,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2007,11,8]],"date-time":"2007-11-08T00:00:00Z","timestamp":1194480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Objectives\u2002<\/jats:bold> The primary objective was to compare the vaginal bleeding pattern during administration of tibolone and low\u2010dose continuous combined estradiol plus norethisterone acetate (E<jats:sub>2<\/jats:sub>\/NETA). The secondary objectives were efficacy on vasomotor symptoms and vaginal atrophy.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> A randomised, double\u2010blind, double\u2010dummy, group comparative intervention trial.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Multicentre study executed in 32 centres in 7 European countries.<\/jats:p><jats:p><jats:bold>Sample\u2002<\/jats:bold> Five hundred and seventy\u2010two healthy symptomatic postmenopausal women, aged 45\u201365 years.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Participants were randomised to receive 2.5 mg tibolone or 1 mg 17\u03b2 estradiol plus 0.5 mg norethisterone acetate (E<jats:sub>2<\/jats:sub>\/NETA) daily for 48 weeks.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> Prevalence of vaginal bleeding, hot flushes and adverse events.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The incidence of bleeding was significantly lower in the tibolone group during the first 3 months of treatment (18.3 versus 33.1%; <jats:italic>P<\/jats:italic> &lt; 0.001) when compared with the E<jats:sub>2<\/jats:sub>\/NETA group. This effect on the bleeding pattern was sustained throughout the study, although reaching statistical significance again only in 7\u20139 months of treatment (11 versus 19%; <jats:italic>P<\/jats:italic> &lt; 0.05). In both treatment groups, vasomotor symptoms and vaginal atrophy were significantly reduced to a similar extent when compared with baseline. The prevalence of breast pain\/tenderness was significantly lower with tibolone compared with E<jats:sub>2<\/jats:sub>\/NETA (3.2 versus 9.8%; <jats:italic>P<\/jats:italic> &lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Tibolone reduces menopausal symptoms to a similar extent as conventional low\u2010dose continuous combined hormone therapy but causes significant less vaginal bleeding in the first 3 months of treatment. This constitutes an important argument for woman adherence to therapy.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2007.01537.x","type":"journal-article","created":{"date-parts":[[2007,11,8]],"date-time":"2007-11-08T12:58:41Z","timestamp":1194526721000},"page":"1522-1529","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Tibolone and low\u2010dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability"],"prefix":"10.1111","volume":"114","author":[{"given":"ML","family":"Hammar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Van De Weijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HR","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Pornel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EMJ","family":"Von Mauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EA","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"TOTAL Study Investigators Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,8]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(92)90003-M"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200205000-00003"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1996.tb09555.x"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0023"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2004.02.012"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(02)00112-5"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2002.01338.x"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10237.x"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(01)00606-2"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.121896"},{"key":"e_1_2_10_13_2","first-page":"299","article-title":"Meeting the evolving therapeutic needs of postmenopausal women","volume":"18","author":"Ettinger B","year":"2000","journal-title":"J Bone Miner Metab"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb10929.x"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(00)70210-9"},{"issue":"2","key":"e_1_2_10_16_2","first-page":"96","article-title":"The European Menopause Survey 2005: what do women think right now about menopause and HRT?","volume":"8","author":"Genazzani AR","year":"2005","journal-title":"Climacteric"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(02)00203-7"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004180"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-199909000-00001"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200201000-00004"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-199902000-00019"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-199906040-00005"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/cmt.5.1.60.69"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2005.02.011"},{"key":"e_1_2_10_25_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jcem.87.1.8141","article-title":"Tibolone for postmenopausal women: systematic review of randomized trials","volume":"87","author":"Modelska K","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"e_1_2_10_26_2","first-page":"1","article-title":"Livial: a review of clinical studies","volume":"106","author":"Moore RA","year":"1999","journal-title":"Br J Obstet Gynecol"},{"key":"e_1_2_10_27_2","first-page":"11","article-title":"Hormone replacement therapy: aspects of bleeding problems and compliance","volume":"41","author":"Samsioe G","year":"1996","journal-title":"Int J Fertil Menopausal Stud"},{"key":"e_1_2_10_28_2","first-page":"102","article-title":"Compliance considerations with hormone replacement therapy","volume":"5","author":"Karakoc B","year":"1998","journal-title":"Menopause"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2000.104767"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0962279901000254"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-199904000-00016"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)49880-8"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2003.05.028"},{"key":"e_1_2_10_34_2","first-page":"305","article-title":"Thrombospondin\u20101 and 2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis","volume":"19","author":"Seki N","year":"2001","journal-title":"Int J Oncol"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2002.02020.x"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(99)00643-2"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2207"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200205000-00004"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2007.01537.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2007.01537.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T16:24:05Z","timestamp":1697041445000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2007.01537.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,8]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1471-0528.2007.01537.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2007.01537.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,8]]},"assertion":[{"value":"2007-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}